Clinical Trial Update: Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating sildenafil for pulmonary hypertension associated with idiopathic pulmonary fibrosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis | Phase 4 | Status: WITHDRAWN